Long-term subcutaneous recombinant interleukin-2 as maintenance therapy: Biological effects and clinical implications

M. Guida, I. Abbate, M. D. Musci, A. Casamassima, A. Latorre, V. Lorusso, M. Correale, M. De Lena

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Several trials have evaluated the therapeutic efficacy of rIL-2 combined with more traditional treatments such as chemotherapy and radiotherapy, but the use of lL-2 as adjuvant therapy for minimal residual disease or to maintain clinical response obtained with other standard treatments has yet to be investigated. The aim of the present trial was to study the biological effects of maintenance long-term treatment (6 months) with subcutaneous low- dose IL-2 in 16 patients with different neoplasms previously treated with chemo-immuno therapeutic regimens or with surgery (7 metastatic renal cancers, 5 locally advanced renal cancers previously subjected to radical nephrectomy, 2 metastatic breast cancers, 1 small cell lung cancer, and 1 metastatic melanoma). Clinical tolerability, feasibility and therapeutic implications are also discussed. The IL-2 schedule was as follows: 4.5 million IU/day, 3 times weekly for 6 months. A total of 14 patients completed therapy without requiring dose modifications and are free of progression after a median duration of 8+ months (range: 7+ to 34+) while two patients progressed during therapy (one inflammatory breast cancer and one renal cancer). Important and persistent hemato-immunostimulating effects in both soluble (IL-2, sIL-2R, IL-6) and cellular (lymphocyte subsets, monocytes, eosinophils) parameters were noted during the entire treatment. The IL-2 related toxicity was quite low. Moreover, this long-term IL-2 therapy could control neoplastic growth and thus prolong clinical response obtained with standard treatments. Prospective randomized studies regarding the clinical efficacy have been initiated.

Original languageEnglish
Pages (from-to)195-203
Number of pages9
JournalCancer Biotherapy
Volume10
Issue number3
Publication statusPublished - 1995

Fingerprint

Biological Therapy
Interleukin-2
Kidney Neoplasms
Therapeutics
Inflammatory Breast Neoplasms
Lymphocyte Subsets
Small Cell Lung Carcinoma
Residual Neoplasm
Nephrectomy
Eosinophils
Monocytes
Melanoma
Interleukin-6
Appointments and Schedules
Radiotherapy
Maintenance

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Long-term subcutaneous recombinant interleukin-2 as maintenance therapy : Biological effects and clinical implications. / Guida, M.; Abbate, I.; Musci, M. D.; Casamassima, A.; Latorre, A.; Lorusso, V.; Correale, M.; De Lena, M.

In: Cancer Biotherapy, Vol. 10, No. 3, 1995, p. 195-203.

Research output: Contribution to journalArticle

@article{b7dbd60be9bd40f6818d00d82b39457c,
title = "Long-term subcutaneous recombinant interleukin-2 as maintenance therapy: Biological effects and clinical implications",
abstract = "Several trials have evaluated the therapeutic efficacy of rIL-2 combined with more traditional treatments such as chemotherapy and radiotherapy, but the use of lL-2 as adjuvant therapy for minimal residual disease or to maintain clinical response obtained with other standard treatments has yet to be investigated. The aim of the present trial was to study the biological effects of maintenance long-term treatment (6 months) with subcutaneous low- dose IL-2 in 16 patients with different neoplasms previously treated with chemo-immuno therapeutic regimens or with surgery (7 metastatic renal cancers, 5 locally advanced renal cancers previously subjected to radical nephrectomy, 2 metastatic breast cancers, 1 small cell lung cancer, and 1 metastatic melanoma). Clinical tolerability, feasibility and therapeutic implications are also discussed. The IL-2 schedule was as follows: 4.5 million IU/day, 3 times weekly for 6 months. A total of 14 patients completed therapy without requiring dose modifications and are free of progression after a median duration of 8+ months (range: 7+ to 34+) while two patients progressed during therapy (one inflammatory breast cancer and one renal cancer). Important and persistent hemato-immunostimulating effects in both soluble (IL-2, sIL-2R, IL-6) and cellular (lymphocyte subsets, monocytes, eosinophils) parameters were noted during the entire treatment. The IL-2 related toxicity was quite low. Moreover, this long-term IL-2 therapy could control neoplastic growth and thus prolong clinical response obtained with standard treatments. Prospective randomized studies regarding the clinical efficacy have been initiated.",
author = "M. Guida and I. Abbate and Musci, {M. D.} and A. Casamassima and A. Latorre and V. Lorusso and M. Correale and {De Lena}, M.",
year = "1995",
language = "English",
volume = "10",
pages = "195--203",
journal = "Cancer Biotherapy",
issn = "1062-8401",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Long-term subcutaneous recombinant interleukin-2 as maintenance therapy

T2 - Biological effects and clinical implications

AU - Guida, M.

AU - Abbate, I.

AU - Musci, M. D.

AU - Casamassima, A.

AU - Latorre, A.

AU - Lorusso, V.

AU - Correale, M.

AU - De Lena, M.

PY - 1995

Y1 - 1995

N2 - Several trials have evaluated the therapeutic efficacy of rIL-2 combined with more traditional treatments such as chemotherapy and radiotherapy, but the use of lL-2 as adjuvant therapy for minimal residual disease or to maintain clinical response obtained with other standard treatments has yet to be investigated. The aim of the present trial was to study the biological effects of maintenance long-term treatment (6 months) with subcutaneous low- dose IL-2 in 16 patients with different neoplasms previously treated with chemo-immuno therapeutic regimens or with surgery (7 metastatic renal cancers, 5 locally advanced renal cancers previously subjected to radical nephrectomy, 2 metastatic breast cancers, 1 small cell lung cancer, and 1 metastatic melanoma). Clinical tolerability, feasibility and therapeutic implications are also discussed. The IL-2 schedule was as follows: 4.5 million IU/day, 3 times weekly for 6 months. A total of 14 patients completed therapy without requiring dose modifications and are free of progression after a median duration of 8+ months (range: 7+ to 34+) while two patients progressed during therapy (one inflammatory breast cancer and one renal cancer). Important and persistent hemato-immunostimulating effects in both soluble (IL-2, sIL-2R, IL-6) and cellular (lymphocyte subsets, monocytes, eosinophils) parameters were noted during the entire treatment. The IL-2 related toxicity was quite low. Moreover, this long-term IL-2 therapy could control neoplastic growth and thus prolong clinical response obtained with standard treatments. Prospective randomized studies regarding the clinical efficacy have been initiated.

AB - Several trials have evaluated the therapeutic efficacy of rIL-2 combined with more traditional treatments such as chemotherapy and radiotherapy, but the use of lL-2 as adjuvant therapy for minimal residual disease or to maintain clinical response obtained with other standard treatments has yet to be investigated. The aim of the present trial was to study the biological effects of maintenance long-term treatment (6 months) with subcutaneous low- dose IL-2 in 16 patients with different neoplasms previously treated with chemo-immuno therapeutic regimens or with surgery (7 metastatic renal cancers, 5 locally advanced renal cancers previously subjected to radical nephrectomy, 2 metastatic breast cancers, 1 small cell lung cancer, and 1 metastatic melanoma). Clinical tolerability, feasibility and therapeutic implications are also discussed. The IL-2 schedule was as follows: 4.5 million IU/day, 3 times weekly for 6 months. A total of 14 patients completed therapy without requiring dose modifications and are free of progression after a median duration of 8+ months (range: 7+ to 34+) while two patients progressed during therapy (one inflammatory breast cancer and one renal cancer). Important and persistent hemato-immunostimulating effects in both soluble (IL-2, sIL-2R, IL-6) and cellular (lymphocyte subsets, monocytes, eosinophils) parameters were noted during the entire treatment. The IL-2 related toxicity was quite low. Moreover, this long-term IL-2 therapy could control neoplastic growth and thus prolong clinical response obtained with standard treatments. Prospective randomized studies regarding the clinical efficacy have been initiated.

UR - http://www.scopus.com/inward/record.url?scp=0029122468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029122468&partnerID=8YFLogxK

M3 - Article

C2 - 8547958

AN - SCOPUS:0029122468

VL - 10

SP - 195

EP - 203

JO - Cancer Biotherapy

JF - Cancer Biotherapy

SN - 1062-8401

IS - 3

ER -